Vancouver, British Columbia – June 26, 2015 – Sirona Biochem Corp. (“Sirona”) or the “Company”) (TSX-V: SBM) (FSE: ZSB) is pleased to announce the appointment of Mr. Casper Bych to its Board of Directors.
Mr. Bych has more than 20 years’ experience in management and in the legal and financial industry in Europe, South and North America. Casper is the President and CEO of Mountainview Capital Corporation, a Vancouver based corporate finance boutique that raises funds for public companies, private cash flow companies and private companies in the process of going public. Mountainview Capital has acted for companies in the resource sector, energy and medical device sectors in North and South America. Mountainview Capital also provides financial advisory services in connection with project financings and acts as management consultant for companies in the process of going public or undergoing M&A transactions.
Prior to founding Mountainview Capital, Mr. Bych was a securities lawyer in Vancouver. His practice was primarily focused on the healthcare, resource and technology sector, where he took companies public and acted for publicly traded companies.
Mr. Bych holds law degrees from University of Copenhagen (Cand Jur) and McGill University.
The Company also announces that Mr. Nigel Terrett has resigned as a director. The Company’s thanks Mr. Terrett for his work over the past few years.
The Company also announces that it has granted incentive stock options under its stock option plan to directors, officers and employees of the company for the purchase of 4,200,000 common shares of the Company at a price of $0.16 per share. 3,600,000 of the options are for a ten year period, 600,000 are for a two year period.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.